Antibody persistency and trend post-SARS-CoV-2 infection at eight months
Keywords:
SARS-CoV-2, COVID-19, coronavirus, antibody trend, immunityAbstract
Introduction. A large amount of recent research has focused on the nature of immunity elicited by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, particularly its robustness and the duration of protection it offers. As a vaccine’s efficacy relies on its ability to induce a protective immune response, these questions remain particularly pertinent. An improved understanding of the immunity offered by the antibodies developed against SARS-CoV-2 in recovered patients is critical for the development of diagnostic tests and vaccines.
Methods. Our study aimed at the longitudinal analysis of antibody presence, persistence and its trend over eight months in a group of 30 COVID-19 recovered patients who tested positive by real-time quantitative PCR for SARS-CoV-2 in the period 1-30 March 2020. The subjects were divided into two groups based on disease severity: mild (n=17 subjects) and moderately-severe (n=13 subjects). The MAGLUMI 2019-nCoV lgM/lgG chemiluminescent analytical system (CLIA) assay was used to analyze these antibody titres. Results. IgG antibody persistency was demonstrated in 76.7 % of the subjects (23 out of 30) at eight months post-infection. For the moderately-severe group, the titre trends for both IgM and IgG changed in a statistically significant way throughout the time period with IgM below and IgG above the set cut-off.
Conclusions. The results of this study highlight an important point in terms of the association between humoral immune response and disease severity. Patients who have experienced a relatively severe infection might develop a stronger immune response that could persist for a longer period.
References
1. Mandavilli A. Immunity of the Coronavirus May Last Years, New Data Int. 2020 Nov 17. Last update 2020 Nov 27. Available on: https://www. nytimes.com/2020/11/17/health/coronavirusimmunity.html [Last accessed: 2021 February
27]
2. Choe PG, Kim KH, Kang CK, et al. Antibody responses 8 months after asymptomatic or mild SARS-CoV-2 infection. Emerg Infect Dis 2021 Mar; 27(83): 928-31. doi: 10.3201/ eid2703.204543. Epub 2020 Dec 22.
3. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021 Feb 5; 371(6529):eabf4063. doi: 10.1126/science. abf4063. Epub 2021 Jan 6. PMID: 33408181; PMCID: PMC7919858.
4. World Health Organization (WHO). Global surveillance for COVID-19 caused by human
infection with COVID-19 virus: interim guidance. 20 March 2020. WHO/2019-nCoV/ SurveillanceGuidance/2020.6. Available on: https://www.who.int/publications/i/item/globalsurveillance-for-human-infection-with-novelcoronavirus-(2019-ncov) [Last accessed: 2021 February 7].
5. M5001E01-MAGLUMI 2019-nCoV IgGIgM200316 (drgmedtek.pl), MAGLUMI 2019-nCoV IgM/IgG - Letter of Authorization (fda.gov)
6. Suthar MS, Zimmerman MG, Kauffman RC, et. al. Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients. Cell Med Rep 2020 Jun 23; 1(3): 100040.doi: 10.1016/j.
xcrm.2020.100040. Epub 2020 Jun 8.
7. Seydoux E, Homad, LJ, MacCamy AJ, et. al.
Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. Immunity 2020 Jul 14; 53(1): 98-105.e5. doi: 10.1016/j.immuni.2020.06.001. Epub 2020 Jun 8.
8. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021 Feb 5; 371(6529): eabf4063. doi: 10.1126/science.
abf4063. Epub 2021 Jan 6.
9. Hartley GE, Edwards ESJ, Aui PM, et al. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Sci Immunol 2020 Dec 22; 5(54): eabf8891. doi: 10.1126/ sciimmunol.abf8891.
10. Zhang X, Lu S, Li H, et al. Viral and antibody kinetics of COVID-19 patients with different disease severities in acute and convalescent phases: a 6-month follow-up study. Virol Sin 2020 Dec 6; 35(6): 820-9. doi: 10.1007/s12250-020-00329-9.
Epub 2020 Dec 22.
11. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N Engl J Med 2020 Sep 10; 383(11): 1085-77. doi:10.1056/ NEJMc2025179pmid:32706954. Epub 2020 Jul 21.
12. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients with Novel Coronavirus Disease 2019. Clin Infect Dis 2020 Nov 19; 71(16): 2027-34. doi: 10.1093/cid/ ciaa344.
13. Liang L, Yang B, Jiang N, et al. Three-month follow-up study of survivors of coronavirus disease 2019 after discharge. J Korean Med Sci 2020 Dec 7; 35(47): e418. doi: 10.3346/ jkms.2020.35.e418.
14. Yang OO, Ibarrondo FJ. Loss of Anti-SARSCoV-2 Antibodies in Mild Covid-19. Reply. N Engl J Med 2020 oct 22; 383(17): 1697-8. Reply. doi: 10.1056/NEJMc2027051. Epub 2020 Sep 23.
15. Campion EW, Scott L, Bowab C, et al. The New NEJM.org. N Engl J Med 2010 Aug 12; 363(7): 677-8. doi: 10.1056/NEJMe1007409. Epub 2010 Jul 24.
16. Wu J, Liang B, Chen C, et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. Nat Commun 2021 Mar 22; 12(1): 1813. doi: 10.1038/s41467-021 -22034-1.
17. Lisboa Bastos M, Tavaziva G, Abidi SK, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis.
BMJ 2020 Jul 1; 370: m2516. doi: 10.1136/bmj. m2516.
18. Genomic epidemiology of novel coronavirus - Europe-focused subsampling. (n.d.). Available on: https://nextstrain.org/ncov/europe?f_ country=Italy and https://www.gisaid.org/ hcov19-variants/ [Last accessed: 2021 March 10].
19. Garcia-Beltran WF, Lam EC, Denis KS, et al. Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 2021 Mar 12: S0092-8674(21)00298-1. doi: 10.1016/j.cell.2021.03.013. Epub ahead of print.
20. Moyo-Gwete T, Madzivhandila M, Makhado Z, et al. SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies. bioRxiv [Preprint not peer reviewed] 2021 Mar 6; 2021.03.06.434193; doi: https://doi. org/10.1101/2021.03.06.434193.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.